India faces a massive economic burden from diabetes, estimated at over 11 trillion US dollars. This figure places India second globally, be...

India faces a significant diabetes crisis, with millions undiagnosed, increasing the risk of heart disease. Early detection through screeni...

Zerodha CEO Nithin Kamath raised concern over surging soft drink consumption in India, citing Coca-Cola's strong Q1 growth and linking it t...

Eli Lilly will launch Mounjaro in India in 2025. The drug treats type 2 diabetes and obesity. Lilly received marketing authorization in Jul...

Zerodha CEO Nithin Kamath raises concern about the increasing number of diabetes cases in India. He highlights the alarming statistics and ...

Replacing ultra-processed foods with unprocessed or minimally processed food lowers diabetes risk, confirms a Lancet Regional Health study....

Is diabetes management all about monitoring glucose levels or much more? Is diabetes management a 100-metre sprint or a lifelong marathon? ...

More than 14.1 million type 2 diabetes cases in 2018 were attributed to poor diet, representing over 70% of new diagnoses worldwide, accord...

The burden of obesity in urban India is increasing alarmingly and around 21% of the total population is over weight.

As per WHO, non-communicable diseases or chronic diseases, such as cancer, heart ailments, respiratory diseases, diabetes, kill 38 mn peopl...

The health ministry has chalked out National Multi-Sectoral Action with the aim to reduce deaths from cancer, heart diseases by 25%.

The economic burden of diabetes is high in India as most patients pay out-of-pocket, and due to lack of medical reimbursement.

A completely new drug in the 'gliptin' family has disrupted the anti-diabetes market by lowering the cost of therapy for patients by 80%.

Data shows diabetes is now among the top ten reasons for various other disorders among both men and women as it breeds obesity and stroke.

A new anti-diabetes drug from the 'gliptin' family soon to be launched in India promises to lower treatment cost for patients by 55-60%.

Pharma firm Abbott today said it has inked a three year pact with Puducherry government to improve awareness of non-communicable diseases.

The primary aim of this collaboration is to initiate a health research relationship between the two countries.